LimmaTech Biologics
Chemicals & Related Products · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Grabenstrasse 3, Schlieren, Zurich, 8952...Phone Number
+41 447338585Website
www.lmtbio.comRevenue
$7.4 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About LimmaTech Biologics
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. It was founded as a spin-off of GlycoVaxyn AG, which was acquired by GSK in February 2015 following a two-year collaboration. LimmaTech is developing vaccines exclusively for GSK and actively explores applications of glycoengineering and protein glycosylation technology in other fields.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LimmaTech Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once LimmaTech Biologics has new funding data
Earning: See what the market has to say on LimmaTech Biologics recently announced quarterly report
Check if LimmaTech Biologics has recently received funding, and reach out quickly before it becomes old news!
LimmaTech Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if LimmaTech Biologics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at LimmaTech Biologics
Click to see if LimmaTech Biologics had a recent Job posting/layoffs
Product Launch: Get notified when LimmaTech Biologics launches new products
Recommended Actions
Find VP level buyers at LimmaTech Biologics
Find 3 more new buyers
Company Profile Activity
Activity Insights
LimmaTech Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LimmaTech Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LimmaTech Biologics.
LimmaTech Biologics financials insights
Gather financial insights about LimmaTech Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$40M
LimmaTech Biologics Tech Stack
A closer look at the technologies used by LimmaTech Biologics
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
LimmaTech Biologics News & Media
Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
Saint Herblain (France) and Schlieren (Zurich), November 13, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the first participant has been vaccinated in a Phase 2b controlled human infection model (CHIM) study of Shigella4V2 (S4V2), the world’s most clinically advanced tetravalent bioconjugate shigellosis vacciValneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V
Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V), the world’s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which VaValneva and LimmaTech Enter into a Strategic Partnership to Accelerate the Development of the World’s Most Clinically Advanced Tetravalent Shigella Vaccine Candidate
Saint-Herblain (France) and Schlieren (Zurich), August 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced that the companies have entered into a strategic partnership and exclusive licensing agreement for the development, manufacturing and commercialization of Shigella4V (S4V), a tetravalent bioconjugate vaccine candiLimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V
SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants in low- and middle-income countries. In the nine-month-old target population, administration of S4
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LimmaTech Biologics
Sign Up For FreeTo access detailed company insights
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. It was founded as a spin-off of GlycoVaxyn AG, which was acquired by GSK in Febr... Read More
